Market Closed -
Nasdaq
04:00:00 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
0.7689
USD
|
-0.84%
|
|
+2.51%
|
+13.11%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,370
|
802.5
|
463.8
|
75.22
|
87.22
|
-
|
-
|
Enterprise Value (EV)
1 |
2,014
|
554.3
|
265.4
|
75.22
|
-41.53
|
-132.5
|
-120
|
P/E ratio
|
-14.8
x
|
-4.72
x
|
-2.33
x
|
-0.37
x
|
-1.94
x
|
-2.08
x
|
-1.67
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / EBITDA
|
-28.3
x
|
-3.27
x
|
-1.56
x
|
-0.38
x
|
0.63
x
|
2.41
x
|
-
|
EV / FCF
|
-33
x
|
-5.21
x
|
-1.87
x
|
-
|
0.92
x
|
-
|
-
|
FCF Yield
|
-3.03%
|
-19.2%
|
-53.5%
|
-
|
108%
|
-
|
-
|
Price to Book
|
7.09
x
|
3.65
x
|
2.13
x
|
-
|
0.73
x
|
0.45
x
|
0.48
x
|
Nbr of stocks (in thousands)
|
61,660
|
62,014
|
90,416
|
110,653
|
113,438
|
-
|
-
|
Reference price
2 |
38.44
|
12.94
|
5.130
|
0.6798
|
0.7689
|
0.7689
|
0.7689
|
Announcement Date
|
2/11/21
|
2/10/22
|
2/15/23
|
3/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.165
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-71.24
|
-169.6
|
-170.5
|
-199.5
|
-65.86
|
-55.01
|
-
|
EBIT
1 |
-
|
-71.31
|
-169.8
|
-171.2
|
-199.9
|
-69.61
|
-67.26
|
-59.38
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-69.78
|
-171
|
-169
|
-190.5
|
-41
|
-78.57
|
-53.88
|
Net income
1 |
-23.84
|
-69.78
|
-172
|
-168.7
|
-190.4
|
-45.46
|
-43.27
|
-53.88
|
Net margin
|
-14,447.88%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-12.44
|
-2.590
|
-2.740
|
-2.200
|
-1.830
|
-0.3961
|
-0.3700
|
-0.4600
|
Free Cash Flow
1 |
-
|
-61.05
|
-106.3
|
-142.1
|
-
|
-45
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/3/20
|
2/11/21
|
2/10/22
|
2/15/23
|
3/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-55.7
|
-
|
-44.54
|
-42.86
|
-40.35
|
-
|
-47.22
|
-46.88
|
-62.26
|
-22.84
|
-11
|
-5
|
-3
|
-
|
-
|
EBIT
1 |
-55.8
|
-43.19
|
-44.62
|
-42.95
|
-40.43
|
-43.23
|
-47.3
|
-46.96
|
-69.18
|
-22.84
|
-11
|
-5
|
-3
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-56.93
|
-43.86
|
-44.49
|
-42.07
|
-38.55
|
-41.18
|
-45.27
|
-44.27
|
-59.82
|
-30.3
|
-11
|
-5
|
-3
|
-
|
-
|
Net income
1 |
-57.94
|
-43.86
|
-44.64
|
-42.07
|
-38.14
|
-41.18
|
-45.27
|
-44.27
|
-59.82
|
-30.3
|
-4.29
|
-2.75
|
-1.95
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.9200
|
-0.6900
|
-0.6900
|
-0.5000
|
-0.3700
|
-0.4400
|
-0.4800
|
-0.3900
|
-0.5300
|
-0.2600
|
-0.0400
|
-0.0200
|
-0.0200
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/10/22
|
5/5/22
|
8/4/22
|
11/3/22
|
2/15/23
|
5/4/23
|
8/3/23
|
11/2/23
|
3/15/24
|
5/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
356
|
248
|
198
|
-
|
129
|
220
|
207
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-61
|
-106
|
-142
|
-
|
-45
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-29.4%
|
-59.5%
|
-75%
|
-
|
-43.3%
|
-35.8%
|
-26.2%
|
ROA (Net income/ Total Assets)
|
-
|
-27.4%
|
-52.3%
|
-59.9%
|
-
|
-24%
|
-
|
-
|
Assets
1 |
-
|
255.1
|
328.7
|
281.8
|
-
|
189.6
|
-
|
-
|
Book Value Per Share
2 |
-
|
5.420
|
3.540
|
2.410
|
-
|
1.050
|
1.710
|
1.610
|
Cash Flow per Share
2 |
-
|
-
|
-
|
-
|
-
|
0.1000
|
0.3600
|
-
|
Capex
|
-
|
0.24
|
0.03
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
6/3/20
|
2/11/21
|
2/10/22
|
2/15/23
|
3/15/24
|
-
|
-
|
-
|
Mean consensus UNDERPERFORM Last Close Price
0.7689
USD Average target price
0.975
USD Spread / Average Target +26.80% Consensus |
1st Jan change
|
Capi.
|
---|
| +13.11% | 87.96M | | +9.58% | 115B | | +12.41% | 106B | | -2.59% | 21.96B | | -12.38% | 21.87B | | -5.29% | 19.21B | | -3.35% | 18.08B | | -38.57% | 17.71B | | +7.51% | 14.32B | | +35.67% | 12.42B |
Bio Therapeutic Drugs
|